Skip to main content

Table 3 Comparison of clinical response between ANA titer ≤ 1:80 and ≥ 1:160

From: Correlation of antinuclear antibody and anti-double-stranded DNA antibody with clinical response to infliximab in patients with rheumatoid arthritis: a retrospective clinical study

  ANA titer
  Before IFX After IFX
EULAR ≤ 1:80 ≥ 1:160 P valuea ≤ 1:80 ≥ 1:160 P valuea
response (n = 79) (n = 27)   (n = 56) (n = 38)  
Good 66% 26% < 0.001 77% 11% < 0.001
(remission) (16%) (7%) < 0.001 (59%) (3%) < 0.001
Moderate 9% 33% < 0.001 7% 29% < 0.001
No 25% 41% < 0.001 16% 60% < 0.001
  1. ANA, antinuclear antibodies; IFX, infliximab; aAnalyzed with a χ2 test.